1031-37-4 Usage
General Description
1-benzyl-4-(propylamino)piperidine-4-carboxamide is a chemical compound with the molecular formula C18H28N2O, belonging to the class of piperidine compounds. It is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5). 1-benzyl-4-(propylamino)piperidine-4-carboxamide has been studied for its potential therapeutic effects in various neurological and psychiatric disorders, including anxiety, depression, and schizophrenia. It has shown promise in preclinical studies for its ability to regulate glutamatergic neurotransmission, which plays a crucial role in the pathophysiology of these conditions. Additionally, it exhibits favorable pharmacokinetic properties and has shown minimal side effects in animal studies, making it a potential candidate for further drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 1031-37-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,3 and 1 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1031-37:
(6*1)+(5*0)+(4*3)+(3*1)+(2*3)+(1*7)=34
34 % 10 = 4
So 1031-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H25N3O/c1-2-10-18-16(15(17)20)8-11-19(12-9-16)13-14-6-4-3-5-7-14/h3-7,18H,2,8-13H2,1H3,(H2,17,20)
1031-37-4Relevant articles and documents
Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system
Mavunkel, Babu J.,Lu, Zhijian,Goehring, R. Richard,Lu, Songfeng,Chakravarty, Sarvajit,Perumattam, John,Novotny, Elizabeth A.,Connolly, Maureen,Valentine, Heather,Kyle, Donald J.
, p. 3169 - 3173 (2007/10/03)
A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, and aralkyl-substituted 1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acids as amino acid surrogates to replace the Pro2-Pro3-Gly4-Phe5 section of the peptide bradykinin B2 receptor antagonist [Pro3, Phe5]HOE 140 (D-Arg0-Arg1- Pro2-Pro3-Gly4-Phe5-Ser6-D-Tic7-Oic8-Arg9) were prepared. These psuedopeptides were examined in vitro for their B2 receptor affinities as well as for their ability to block bradykinin mediated actions in vivo. Two compounds in particular, NPC 18521 (I) and NPC 18688 (V) were quite potent in these latter assays, indicating that a significant portion of this prototypical second generation decapeptide antagonist can be replaced with a more compact nonpeptide molecule.
